Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio Inc reported a $116.8M net loss for fiscal 2025.
See the full ACET financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio (ACET) will participate in a fireside chat at the H.C.
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference being held from September 14-16, 2026, in New York.
Details of the event are as follows: Date: Tuesday, September 15, 2026 Time: 3:00 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
gamma delta t cellmedical
A gamma delta T cell is a type of white blood cell that acts like a specialized security guard in the immune system, detecting and responding to infected or damaged cells in ways that differ from the more common immune cells. Investors track them because they are targets for experimental therapies, diagnostics and biomarkers in cancer and infectious disease: advances or setbacks in this area can affect the value of biotech companies and drug pipelines.
chimeric antigen receptorsmedical
Engineered proteins added to a patient’s immune cells that act like a custom “GPS and ID badge,” letting those cells find and attach to specific markers (antigens) on abnormal cells and trigger their destruction. Chimeric antigen receptors are the core technology behind CAR-T and related cell therapies; they matter to investors because they drive clinical potential, regulatory review, manufacturing complexity, costs, and commercial value in targeted immunotherapies.
in vivo car-tmedical
In vivo CAR‑T is a cancer immunotherapy approach that delivers genetic instructions directly into a patient’s body so their own immune cells are reprogrammed on site to recognize and kill cancer cells, instead of removing and engineering those cells in a lab. For investors, it matters because this method could make CAR‑T treatments faster, cheaper and easier to scale—potentially expanding the market—but it also introduces different safety, manufacturing and regulatory risks that affect commercial viability.
